Increasing access to specialty care for rare diseases: a case study using a foundation sponsored clinic network for patients with neurofibromatosis 1, neurofibromatosis 2, and schw...

by Vanessa L. Merker, Annie Dai, Heather B. Radtke, Pamela Knight, Justin T. Jordan, Scott R. Plotkin
Published 2018-08-01

Pseudoprogression of Malignant Peripheral Nerve Sheath Tumor in Patient with Neurofibromatosis Type 1, a Case Report

by Andrés J. Lessing, Gregory M. Cote, Thomas F. DeLaney, Scott R. Plotkin, Kevin A. Raskin, Juan N. Lessing
Published 2021-09-01

Modeling NF2 with human arachnoidal and meningioma cell culture systems: NF2 silencing reflects the benign character of tumor growth

by Marianne F. James, Johanna M. Lelke, Mia MacCollin, Scott R. Plotkin, Anat O. Stemmer-Rachamimov, Vijaya Ramesh, James F. Gusella
Published 2008-02-01

The impact of the COVID-19 pandemic on neurofibromatosis clinical care and research

by Heather B. Radtke, Bonita P. Klein-Tasman, Vanessa L. Merker, Pamela Knight, Nicole J. Ullrich, Justin T. Jordan, Bruce Korf, Scott R. Plotkin
Published 2021-02-01

Bevacizumab treatment for meningiomas in NF2: a retrospective analysis of 15 patients.

by Fabio P Nunes, Vanessa L Merker, Dominique Jennings, Paul A Caruso, Emmanuelle di Tomaso, Alona Muzikansky, Fred G Barker, Anat Stemmer-Rachamimov, Scott R Plotkin
Published 2013-01-01

Transcriptomic signature of painful human neurofibromatosis type 2 schwannomas

by Phanidhar Kukutla, Sherif G. Ahmed, Daniel M. DuBreuil, Ahmed Abdelnabi, Murat Cetinbas, Giulia Fulci, Berent Aldikacti, Anat Stemmer‐Rachamimov, Scott R. Plotkin, Brian Wainger, Ruslan I. Sadreyev, Gary J. Brenner
Published 2021-07-01

Quantitative assessment of whole-body tumor burden in adult patients with neurofibromatosis.

by Scott R Plotkin, Miriam A Bredella, Wenli Cai, Ara Kassarjian, Gordon J Harris, Sonia Esparza, Vanessa L Merker, Lance L Munn, Alona Muzikansky, Manor Askenazi, Rosa Nguyen, Ralph Wenzel, Victor F Mautner
Published 2012-01-01

Early changes in glioblastoma metabolism measured by MR spectroscopic imaging during combination of anti-angiogenic cediranib and chemoradiation therapy are associated with surviva...

by Ovidiu C. Andronesi, Morteza Esmaeili, Ronald J. H. Borra, Kyrre Emblem, Elizabeth R. Gerstner, Marco C. Pinho, Scott R. Plotkin, Andrew S. Chi, April F. Eichler, Jorg Dietrich, S. Percy Ivy, Patrick Y. Wen, Dan G. Duda, Rakesh Jain, Bruce R. Rosen, Gregory A. Sorensen, Tracy T. Batchelor
Published 2017-06-01

Traditional and systems biology based drug discovery for the rare tumor syndrome neurofibromatosis type 2.

by Synodos for NF2 Consortium, Robert Allaway, Steve P Angus, Roberta L Beauchamp, Jaishri O Blakeley, Marga Bott, Sarah S Burns, Annemarie Carlstedt, Long-Sheng Chang, Xin Chen, D Wade Clapp, Patrick A Desouza, Serkan Erdin, Cristina Fernandez-Valle, Justin Guinney, James F Gusella, Stephen J Haggarty, Gary L Johnson, Salvatore La Rosa, Helen Morrison, Alejandra M Petrilli, Scott R Plotkin, Abhishek Pratap, Vijaya Ramesh, Noah Sciaky, Anat Stemmer-Rachamimov, Tim J Stuhlmiller, Michael E Talkowski, D Bradley Welling, Charles W Yates, Jon S Zawistowski, Wen-Ning Zhao
Published 2018-01-01

Brigatinib causes tumor shrinkage in both NF2-deficient meningioma and schwannoma through inhibition of multiple tyrosine kinases but not ALK.

by Long-Sheng Chang, Janet L Oblinger, Abbi E Smith, Marc Ferrer, Steven P Angus, Eric Hawley, Alejandra M Petrilli, Roberta L Beauchamp, Lars Björn Riecken, Serkan Erdin, Ming Poi, Jie Huang, Waylan K Bessler, Xiaohu Zhang, Rajarshi Guha, Craig Thomas, Sarah S Burns, Thomas S K Gilbert, Li Jiang, Xiaohong Li, Qingbo Lu, Jin Yuan, Yongzheng He, Shelley A H Dixon, Andrea Masters, David R Jones, Charles W Yates, Stephen J Haggarty, Salvatore La Rosa, D Bradley Welling, Anat O Stemmer-Rachamimov, Scott R Plotkin, James F Gusella, Justin Guinney, Helen Morrison, Vijaya Ramesh, Cristina Fernandez-Valle, Gary L Johnson, Jaishri O Blakeley, D Wade Clapp, Synodos for NF2 Consortium
Published 2021-01-01